Wednesday, 20 March 2013

AAN 2013 San Diego: daclizumab extension study results

"The following is my platform presentation from the AAN in San Diego. I presented it yesterday afternoon. You may find the information in the slides useful."



"Why is daclizumab so interesting? It has a greater impact on disability progression than you would expect from it impact on relapses. It also has a very interesting mechanism of action; it boosts a population of cells called natural killer cells (NK-cells) that are part of the innate or hard-wired immune system. NK-cells have several functions one of which is an anti-viral role. Could the fact that daclizumab increases NK-cells, which correlates with the drug's effectiveness, be telling us something fundamental about MS? Yes, I think so. Could MS be due to a virus and daclizumab is boosting the anti-viral response against this virus? Yes, this is the premise that underpins The Charcot Project."

"Because of daclizumab's impact on disability progression, that may be independent of relapses, it needs to be tried in SPMS. Let's hope Biogen-Idec and AbbVie have the will, and then the resources, to take-on SPMS or even PPMS with daclizumab."

CoI: multiple

4 comments:

  1. Thanks for posting this. Just curious: Are you also looking at differences in brain atrophy in these subjects?

    ReplyDelete
    Replies
    1. Yes, brain atrophy data will be forthcoming.

      Delete
  2. Dr. Patrick Oschman? Prof. Dr. Partick Oschmann??
    He is my Neurologist at the local MS-centre.

    I have prog. relapsing MS and Mitoxantrone is due by the end of the year. So I am looking for alternatives (besides Cyclophosphamide). Are there any inclinations to test Daclizumab for spMS or prMS???

    ReplyDelete
    Replies
    1. If the RRMS phase 3 study is positive we are hoping Biogen-Idec and Abbvie take the plunge and take Daclizumab into SPMS.

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.